← Back to Search

Combination Product

Combination Wound Care for Hidradenitis Suppurativa

Phase 2
Waitlist Available
Led By Rita O Pichardo, MD
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Individuals with hidradenitis suppurativa with non-healing wounds or draining abscesses/nodules
Be older than 18 years old
Must not have
Individuals younger than 18 years of age
Individuals without a diagnosis of HS
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from week 4 to week 8
Awards & highlights

Study Summary

This trial is testing a combination wound care product of methylene blue, gentian violet, and ovine forestomach to see how well it heals wounds.

Who is the study for?
This trial is for adults over 18 with hidradenitis suppurativa (HS) who have non-healing wounds or draining abscesses/nodules. It's not open to those under 18 or without an HS diagnosis.Check my eligibility
What is being tested?
The study is testing the effectiveness of a wound care regimen using methylene blue, gentian violet, and ovine forestomach dressings on healing HS-related wounds.See study design
What are the potential side effects?
Potential side effects may include skin irritation, allergic reactions to the dressing materials, and discoloration of the skin where treatments are applied.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have hidradenitis suppurativa with wounds or abscesses that won't heal.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am under 18 years old.
Select...
I have not been diagnosed with hidradenitis suppurativa (HS).

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from week 4 to week 8
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from week 4 to week 8 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent of Wound Healing
Wound Healing Time
Secondary outcome measures
Pain Assessment

Trial Design

1Treatment groups
Experimental Treatment
Group I: TreatmentExperimental Treatment1 Intervention
methylene blue, gentian violet, and ovine forestomach wound dressings to HS lesions

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The combination of Endoform, Hydrofera Blue, and Hypafix tape leverages the antimicrobial properties of methylene blue and gentian violet, along with the wound healing benefits of ovine forestomach. Methylene blue and gentian violet act as antiseptics, reducing bacterial load and preventing infection, which is crucial for managing the chronic and recurrent nature of HS lesions. The ovine forestomach component promotes tissue regeneration and wound healing. These mechanisms are vital for HS patients as they help control infection, reduce inflammation, and enhance healing of the painful and persistent wounds characteristic of the condition. Other common treatments, such as antibiotics, biologics, and surgical interventions, also aim to reduce inflammation, control infection, and promote healing, addressing the multifaceted pathology of HS.
Management of hidradenitis suppurativa.

Find a Location

Who is running the clinical trial?

Wake Forest University Health SciencesLead Sponsor
1,253 Previous Clinical Trials
1,010,927 Total Patients Enrolled
3 Trials studying Hidradenitis Suppurativa
83 Patients Enrolled for Hidradenitis Suppurativa
Rita O Pichardo, MDPrincipal InvestigatorWake Forest University Health Sciences
1 Previous Clinical Trials
1 Trials studying Hidradenitis Suppurativa

Media Library

methylene blue, gentian violet, and ovine forestomach wound dressings (Combination Product) Clinical Trial Eligibility Overview. Trial Name: NCT04354012 — Phase 2
Hidradenitis Suppurativa Research Study Groups: Treatment
Hidradenitis Suppurativa Clinical Trial 2023: methylene blue, gentian violet, and ovine forestomach wound dressings Highlights & Side Effects. Trial Name: NCT04354012 — Phase 2
methylene blue, gentian violet, and ovine forestomach wound dressings (Combination Product) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04354012 — Phase 2
~0 spots leftby Oct 2024